Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00809562 · ClinicalTrials.gov registry record · Phase 2
A Study of RO4917523 in Patients With Treatment Resistant Depression
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT00809562 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 46 participants.
The verdict
NCT00809562, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability and efficacy of RO4917523, in comparison to placebo, in patients with treatment-resistant depression. Following a washout period from existing anti-depressant medication, cohorts of patients will be randomized to receive daily oral RO4917523 at up to five different doses (according to the safety and tolerability observed at the lower doses during the study), or placebo. The anticipated time on study treatment is 10 days (in an inpatient unit), and the target sample size is \<100 individuals.
Interventions
- DRUG Placebo
- DRUG RO4917523
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2009-03 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00809562
The ClinicalTrials.gov registry entry for NCT00809562 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00809562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00809562 about?
NCT00809562 is a clinical study titled "A Study of RO4917523 in Patients With Treatment Resistant Depression". This study will evaluate the safety, tolerability and efficacy of RO4917523, in comparison to placebo, in patients with treatment-resistant depression. Following a washout period from existing anti-depressant medication, cohorts of patients will be randomized to receive daily oral RO4917523 at up to...
What is the current status of trial NCT00809562?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2009-03. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00809562?
The interventions under investigation include: Placebo (DRUG), RO4917523 (DRUG).
Who is sponsoring clinical trial NCT00809562?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.